SCHEMBL359134

SCHEMBL359134

CCCCCCCCCCC(=O)O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O

nearest known ligand 0.48

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
LDHA P00338 1/20 0.48
CDK1 P06493 1/20 0.47
CCNB1 P14635 1/20 0.47
EPHX2 P34913 3/20 0.46
TLR4 O00206 1/20 0.41
LY96 Q9Y6Y9 1/20 0.41
AKT1 P31749 1/20 0.41
PRKCA P17252 4/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL33763 1.00 LDHA (0.48) LDHACDK1CCNB1EPHX2TLR4
SCHEMBL359292 1.00 LDHA (0.48) LDHACDK1CCNB1EPHX2TLR4
SCHEMBL16253 1.00 LDHA (0.48) LDHACDK1CCNB1EPHX2TLR4
SCHEMBL15435964 1.00 LDHA (0.48) LDHACDK1CCNB1EPHX2TLR4
SCHEMBL337163 1.00 LDHA (0.48) LDHACDK1CCNB1EPHX2TLR4
SCHEMBL39624 1.00 LDHA (0.48) LDHACDK1CCNB1EPHX2TLR4
SCHEMBL313538 1.00 LDHA (0.48) LDHACDK1CCNB1EPHX2TLR4
SCHEMBL128339 1.00 LDHA (0.48) LDHACDK1CCNB1EPHX2TLR4
SCHEMBL359493 1.00 LDHA (0.48) LDHACDK1CCNB1EPHX2TLR4
SCHEMBL271582 1.00 LDHA (0.48) LDHACDK1CCNB1EPHX2TLR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3193834-A1 PRE-SPRAY EMULSIONS AND POWDERS CONTAINING NON-POLAR COMPOUNDS VIRUN, INC. (US) 2017-07-26 EP claimed
US-20160193146-A1 COMPOSITIONS CONTAINING NON-POLAR COMPOUNDS VIRUN, INC. 2016-07-07 US claimed
EP-2563164-B1 NANOEMULSION INCLUDING SUCROSE FATTY ACID ESTER VIRUN INC (US) 2016-06-29 EP claimed
WO-2016044813-A9 PRE-SPRAY EMULSIONS AND POWDERS CONTAINING NON-POLAR COMPOUNDS VIRUN, INC. (US) 2016-05-26 WO claimed
US-9320295-B2 Compositions containing non-polar compounds VIRUN, INC. (US) 2016-04-26 US claimed
WO-2016044813-A1 PRE-SPRAY EMULSIONS AND POWDERS CONTAINING NON-POLAR COMPOUNDS VIRUN, INC. (US) 2016-03-24 WO claimed
EP-2811847-A1 BEVERAGE COMPOSITIONS CONTAINING NON-POLAR COMPOUNDS VIRUN, INC. (US) 2014-12-17 EP claimed
US-8741373-B2 Compositions containing non-polar compounds VIRUN, INC. (US) 2014-06-03 US claimed
WO-2013120025-A1 BEVERAGE COMPOSITIONS CONTAINING NON-POLAR COMPOUNDS VIRUN, INC. (US) 2013-08-15 WO claimed
EP-2563164-A1 NANOEMULSION INCLUDING SUCROSE FATTY ACID ESTER VIRUN, INC. (US) 2013-03-06 EP claimed
US-20120016026-A1 Compositions containing non-polar compounds VIRUN, INC. 2012-01-19 US claimed
WO-2011162802-A1 COMPOSITIONS CONTAINING NON-POLAR COMPOUNDS VIRUN, INC. (US) 2011-12-29 WO claimed
WO-2011119228-A1 NANOEMULSION INCLUDING SUCROSE FATTY ACID ESTER VIRUN, INC. (US) 2011-09-29 WO claimed
US-20110236364-A1 Compositions containing non-polar compounds VIRUN, INC. 2011-09-29 US claimed
US-20220338502-A1 EDIBLE SILK AND METHODS OF MAKING AND USING THEREOF EVOLVED BY NATURE, INC. 2022-10-27 US disclosed
EP-4017537-A1 SILK PERSONAL CARE COMPOSITIONS Evolved by Nature, Inc. (US) 2022-06-29 EP disclosed
WO-2021055903-A1 EDIBLE SILK AND METHODS OF MAKING AND USING THEREOF EVOLVED BY NATURE, INC. (US) 2021-03-25 WO disclosed
WO-2011162802-A1 COMPOSITIONS CONTAINING NON-POLAR COMPOUNDS VIRUN, INC. (US) 2011-12-29 WO disclosed
WO-2011119228-A1 NANOEMULSION INCLUDING SUCROSE FATTY ACID ESTER VIRUN, INC. (US) 2011-09-29 WO disclosed
US-20110236364-A1 Compositions containing non-polar compounds VIRUN, INC. 2011-09-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110236364-A1 Compositions containing non-polar compounds ELOVL6, ELOVL3, ELOVL5 LDHA 3297/4885CDK1 1792/4885CCNB1 1229/4885
US-20160193146-A1 COMPOSITIONS CONTAINING NON-POLAR COMPOUNDS ELOVL6, ELOVL3, ELOVL5 LDHA 3297/4885CDK1 1792/4885CCNB1 1229/4885
US-20120016026-A1 Compositions containing non-polar compounds ELOVL6, ELOVL3, ELOVL5 LDHA 1358/4885CDK1 2134/4885CCNB1 951/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.